All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Should Venetoclax based induction regimens be considered SOC for 60+ adults?

Nov 24, 2021

During the 3rd NCRI AML Academy, the AML Hub was pleased to speak with David Taussig, The Royal Marsden Hospital, London, UK. We asked, Should Venetoclax based induction regimens be considered standard of care for 60+ adults?

Should Venetoclax based induction regimens be considered SOC for 60+ adults?

Taussig begins by highlighting that for adults not fit for intensive chemotherapy, evidence favors the use of venetoclax + azatadine. He goes on to outline AML subtypes that can benefit from venetoclax regimens in fit patients, discussing FLT-3 mutations and the BELLINI trial.



Subscribe to get the best content related to AML delivered to your inbox